Keytruda®

Active substance

pembrolizumab

Holder

MSD

Status

closed

Indication

first-line treatment of adult patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) metastatic Colorectal Carcinoma (mCRC)

Public documents

Approbation

Information for the patient

Informed consent

Last update

11/08/2022

Last updated on 03/04/2024